TP53 and non-small cell lung carcinoma: However, in patients who received adjuvant chemotherapy, TP53 mutation was associated with shorter survival than wild‐type TP53. 17, 18A meta‐analysis of 19 studies reported that wild‐type TP53 was associated with a significantly higher OS rate in all stages of NSCLC.